NextCure (NXTC) Liabilities and Shareholders Equity (2018 - 2026)
NextCure (NXTC) posted quarterly Liabilities and Shareholders Equity of $38.0 million for Q1 2026, down 43.43% year-over-year from $67.1 million in Q1 2025, and down 24.32% quarter-over-quarter from $50.2 million in Q4 2025.
NextCure (NXTC) Liabilities and Shareholders Equity (2018 - 2026) Analysis & Trends
NextCure's Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $38.0 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity fell 43.43% year-over-year to $38.0 million; the TTM figure through Mar 2026 stood at $175.5 million (down 48.53% YoY), while the FY2025 annual figure was $50.2 million, down 37.94% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $38.0 million, down from $50.2 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $222.7 million in Q1 2022, with the low at $38.0 million in Q1 2026.
- The 5-year median for Liabilities and Shareholders Equity is $115.2 million (2024), against an average of $119.1 million.
- The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity slipped 23.44% in 2022, then plunged 56.15% in 2025.
- NextCure's Liabilities and Shareholders Equity stood at $184.2 million in 2022, then tumbled by 30.47% to $128.0 million in 2023, then tumbled by 36.85% to $80.9 million in 2024, then slumped by 37.94% to $50.2 million in 2025, then slipped by 24.32% to $38.0 million in 2026.
- Business Quant data shows NXTC's Liabilities and Shareholders Equity at $38.0 million in Q1 2026, $50.2 million in Q4 2025, and $39.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | 22.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.62 Mn |
| Mar 31, 2026 | 37.98 Mn |
| Dec 31, 2025 | 50.18 Mn |
| Sep 30, 2025 | 39.61 Mn |
| Jun 30, 2025 | 47.69 Mn |
| Mar 31, 2025 | 67.14 Mn |
| Dec 31, 2024 | 80.86 Mn |
| Sep 30, 2024 | 90.35 Mn |
| Jun 30, 2024 | 102.59 Mn |
| Mar 31, 2024 | 115.16 Mn |
| Dec 31, 2023 | 128.04 Mn |
| Sep 30, 2023 | 139.94 Mn |
| Jun 30, 2023 | 153.38 Mn |
| Mar 31, 2023 | 167.79 Mn |
| Dec 31, 2022 | 184.16 Mn |
| Sep 30, 2022 | 189.91 Mn |
| Jun 30, 2022 | 206.37 Mn |
| Mar 31, 2022 | 222.75 Mn |
| Dec 31, 2021 | 242.39 Mn |
| Sep 30, 2021 | 257.83 Mn |